Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Chung Sang Tse; Parambir S. Dulai

doi:10.1016/j.gtc.2021.12.005

Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Chung Sang Tse^*, Parambir S. Dulai

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	283-298
Number of pages	16
Journal	Gastroenterology Clinics of North America
Volume	51
Issue number	2
DOIs	https://doi.org/10.1016/j.gtc.2021.12.005
State	Published - Jun 2022

Funding

P.S. Dulai: Consulting and/or grant support from Takeda , Abbvie , Janssen , Pfizer , Gilead , BMS , Lily , Novartis , Scipher , and Prometheus . C.S. Tse has nothing to disclose.

Keywords

Clinical trials
Combination biologics and small molecules
Dual biologic therapies

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.gtc.2021.12.005

Cite this

@article{40e1391cbe03444fb1a0c8af94512c21,

title = "Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease",

keywords = "Clinical trials, Combination biologics and small molecules, Dual biologic therapies",

author = "Tse, {Chung Sang} and Dulai, {Parambir S.}",

note = "Funding Information: P.S. Dulai: Consulting and/or grant support from Takeda , Abbvie , Janssen , Pfizer , Gilead , BMS , Lily , Novartis , Scipher , and Prometheus . C.S. Tse has nothing to disclose.",

year = "2022",

month = jun,

doi = "10.1016/j.gtc.2021.12.005",

language = "English (US)",

volume = "51",

pages = "283--298",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

AU - Tse, Chung Sang

AU - Dulai, Parambir S.

N1 - Funding Information: P.S. Dulai: Consulting and/or grant support from Takeda , Abbvie , Janssen , Pfizer , Gilead , BMS , Lily , Novartis , Scipher , and Prometheus . C.S. Tse has nothing to disclose.

PY - 2022/6

Y1 - 2022/6

KW - Clinical trials

KW - Combination biologics and small molecules

KW - Dual biologic therapies

UR - http://www.scopus.com/inward/record.url?scp=85129842544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129842544&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2021.12.005

DO - 10.1016/j.gtc.2021.12.005

M3 - Review article

C2 - 35595415

AN - SCOPUS:85129842544

SN - 0889-8553

VL - 51

SP - 283

EP - 298

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

IS - 2

ER -

Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this